Global Integrin Inhibitors Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Integrin Inhibitors: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Integrin Inhibitors Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Antibodies
1.2.3 Small Molecules
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Integrin Inhibitors Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cardiovascular Disease
1.3.3 Autoimmune Disease
1.3.4 Tumor
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Integrin Inhibitors Revenue Estimates and Forecasts 2020-2031
2.2 Global Integrin Inhibitors Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Integrin Inhibitors Sales Estimates and Forecasts 2020-2031
2.4 Global Integrin Inhibitors Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Integrin Inhibitors Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Integrin Inhibitors Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Antibodies Market Size by Manufacturers
3.5.2 Small Molecules Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Integrin Inhibitors Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Integrin Inhibitors Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Integrin Inhibitors Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Integrin Inhibitors Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Integrin Inhibitors Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Integrin Inhibitors Sales and Revenue by Type (2020-2031)
6.4 North America Integrin Inhibitors Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Integrin Inhibitors Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Integrin Inhibitors Sales and Revenue by Type (2020-2031)
7.4 Europe Integrin Inhibitors Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Integrin Inhibitors Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Integrin Inhibitors Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Integrin Inhibitors Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Integrin Inhibitors Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Integrin Inhibitors Sales and Revenue by Type (2020-2031)
9.4 Central and South America Integrin Inhibitors Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Integrin Inhibitors Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Integrin Inhibitors Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Integrin Inhibitors Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Integrin Inhibitors Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Integrin Inhibitors Product Models, Descriptions and Specifications
11.1.4 Merck Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Merck Integrin Inhibitors Sales by Product in 2024
11.1.6 Merck Integrin Inhibitors Sales by Application in 2024
11.1.7 Merck Integrin Inhibitors Sales by Geographic Area in 2024
11.1.8 Merck Integrin Inhibitors SWOT Analysis
11.1.9 Merck Recent Developments
11.2 Gland Pharma

Taj Pharmaceuticals
11.2.1 Gland Pharma

Taj Pharmaceuticals Corporation Information
11.2.2 Gland Pharma

Taj Pharmaceuticals Business Overview
11.2.3 Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors Product Models, Descriptions and Specifications
11.2.4 Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors Sales by Product in 2024
11.2.6 Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors Sales by Application in 2024
11.2.7 Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors Sales by Geographic Area in 2024
11.2.8 Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors SWOT Analysis
11.2.9 Gland Pharma

Taj Pharmaceuticals Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Corporation Information
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Integrin Inhibitors Product Models, Descriptions and Specifications
11.3.4 GlaxoSmithKline Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 GlaxoSmithKline Integrin Inhibitors Sales by Product in 2024
11.3.6 GlaxoSmithKline Integrin Inhibitors Sales by Application in 2024
11.3.7 GlaxoSmithKline Integrin Inhibitors Sales by Geographic Area in 2024
11.3.8 GlaxoSmithKline Integrin Inhibitors SWOT Analysis
11.3.9 GlaxoSmithKline Recent Developments
11.4 Takeda
11.4.1 Takeda Corporation Information
11.4.2 Takeda Business Overview
11.4.3 Takeda Integrin Inhibitors Product Models, Descriptions and Specifications
11.4.4 Takeda Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Takeda Integrin Inhibitors Sales by Product in 2024
11.4.6 Takeda Integrin Inhibitors Sales by Application in 2024
11.4.7 Takeda Integrin Inhibitors Sales by Geographic Area in 2024
11.4.8 Takeda Integrin Inhibitors SWOT Analysis
11.4.9 Takeda Recent Developments
11.5 Correvio
11.5.1 Correvio Corporation Information
11.5.2 Correvio Business Overview
11.5.3 Correvio Integrin Inhibitors Product Models, Descriptions and Specifications
11.5.4 Correvio Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Correvio Integrin Inhibitors Sales by Product in 2024
11.5.6 Correvio Integrin Inhibitors Sales by Application in 2024
11.5.7 Correvio Integrin Inhibitors Sales by Geographic Area in 2024
11.5.8 Correvio Integrin Inhibitors SWOT Analysis
11.5.9 Correvio Recent Developments
11.6 Medicure
11.6.1 Medicure Corporation Information
11.6.2 Medicure Business Overview
11.6.3 Medicure Integrin Inhibitors Product Models, Descriptions and Specifications
11.6.4 Medicure Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Medicure Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Integrin Inhibitors Product Models, Descriptions and Specifications
11.7.4 Johnson & Johnson Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Johnson & Johnson Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Corporation Information
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Integrin Inhibitors Product Models, Descriptions and Specifications
11.8.4 Eli Lilly Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Eli Lilly Recent Developments
11.9 Bio-Thera Solutions
11.9.1 Bio-Thera Solutions Corporation Information
11.9.2 Bio-Thera Solutions Business Overview
11.9.3 Bio-Thera Solutions Integrin Inhibitors Product Models, Descriptions and Specifications
11.9.4 Bio-Thera Solutions Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Bio-Thera Solutions Recent Developments
11.10 Biogen
11.10.1 Biogen Corporation Information
11.10.2 Biogen Business Overview
11.10.3 Biogen Integrin Inhibitors Product Models, Descriptions and Specifications
11.10.4 Biogen Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Biogen Recent Developments
11.11 Novartis
11.11.1 Novartis Corporation Information
11.11.2 Novartis Business Overview
11.11.3 Novartis Integrin Inhibitors Product Models, Descriptions and Specifications
11.11.4 Novartis Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Novartis Recent Developments
11.12 Sandoz
11.12.1 Sandoz Corporation Information
11.12.2 Sandoz Business Overview
11.12.3 Sandoz Integrin Inhibitors Product Models, Descriptions and Specifications
11.12.4 Sandoz Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Sandoz Recent Developments
11.13 Polpharma Biologics
11.13.1 Polpharma Biologics Corporation Information
11.13.2 Polpharma Biologics Business Overview
11.13.3 Polpharma Biologics Integrin Inhibitors Product Models, Descriptions and Specifications
11.13.4 Polpharma Biologics Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Polpharma Biologics Recent Developments
11.14 Alvotech
11.14.1 Alvotech Corporation Information
11.14.2 Alvotech Business Overview
11.14.3 Alvotech Integrin Inhibitors Product Models, Descriptions and Specifications
11.14.4 Alvotech Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Alvotech Recent Developments
11.15 Yangtze River Pharmaceutical
11.15.1 Yangtze River Pharmaceutical Corporation Information
11.15.2 Yangtze River Pharmaceutical Business Overview
11.15.3 Yangtze River Pharmaceutical Integrin Inhibitors Product Models, Descriptions and Specifications
11.15.4 Yangtze River Pharmaceutical Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Yangtze River Pharmaceutical Recent Developments
11.16 Lunan Pharma
11.16.1 Lunan Pharma Corporation Information
11.16.2 Lunan Pharma Business Overview
11.16.3 Lunan Pharma Integrin Inhibitors Product Models, Descriptions and Specifications
11.16.4 Lunan Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Lunan Pharma Recent Developments
11.17 Kelun Pharma
11.17.1 Kelun Pharma Corporation Information
11.17.2 Kelun Pharma Business Overview
11.17.3 Kelun Pharma Integrin Inhibitors Product Models, Descriptions and Specifications
11.17.4 Kelun Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Kelun Pharma Recent Developments
11.18 Grand Pharmaceutical
11.18.1 Grand Pharmaceutical Corporation Information
11.18.2 Grand Pharmaceutical Business Overview
11.18.3 Grand Pharmaceutical Integrin Inhibitors Product Models, Descriptions and Specifications
11.18.4 Grand Pharmaceutical Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Grand Pharmaceutical Recent Developments
11.19 Tianjin Chase Sun Pharma
11.19.1 Tianjin Chase Sun Pharma Corporation Information
11.19.2 Tianjin Chase Sun Pharma Business Overview
11.19.3 Tianjin Chase Sun Pharma Integrin Inhibitors Product Models, Descriptions and Specifications
11.19.4 Tianjin Chase Sun Pharma Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.19.5 Tianjin Chase Sun Pharma Recent Developments
11.20 SJZ No.4 Pharmaceutical
11.20.1 SJZ No.4 Pharmaceutical Corporation Information
11.20.2 SJZ No.4 Pharmaceutical Business Overview
11.20.3 SJZ No.4 Pharmaceutical Integrin Inhibitors Product Models, Descriptions and Specifications
11.20.4 SJZ No.4 Pharmaceutical Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.20.5 SJZ No.4 Pharmaceutical Recent Developments
11.21 Huadong Medicin
11.21.1 Huadong Medicin Corporation Information
11.21.2 Huadong Medicin Business Overview
11.21.3 Huadong Medicin Integrin Inhibitors Product Models, Descriptions and Specifications
11.21.4 Huadong Medicin Integrin Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
11.21.5 Huadong Medicin Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Integrin Inhibitors Industry Chain
12.2 Integrin Inhibitors Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Integrin Inhibitors Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Integrin Inhibitors Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Integrin Inhibitors Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Integrin Inhibitors Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Integrin Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Integrin Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Integrin Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Integrin Inhibitors Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Integrin Inhibitors Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Integrin Inhibitors Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Integrin Inhibitors Sales by Region (2020-2025) & (K Units)
Table 8. Global Integrin Inhibitors Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Integrin Inhibitors Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Integrin Inhibitors Sales Share by Manufacturers (2020-2025)
Table 12. Global Integrin Inhibitors Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Integrin Inhibitors Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Integrin Inhibitors by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Integrin Inhibitors as of 2024)
Table 16. Global Integrin Inhibitors Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Integrin Inhibitors Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Integrin Inhibitors Manufacturing Base and Headquarters
Table 19. Global Integrin Inhibitors Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Integrin Inhibitors Sales by Type (2020-2025) & (K Units)
Table 23. Global Integrin Inhibitors Sales by Type (2026-2031) & (K Units)
Table 24. Global Integrin Inhibitors Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Integrin Inhibitors Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Integrin Inhibitors ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Integrin Inhibitors Sales by Application (2020-2025) & (K Units)
Table 29. Global Integrin Inhibitors Sales by Application (2026-2031) & (K Units)
Table 30. Integrin Inhibitors High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Integrin Inhibitors Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Integrin Inhibitors Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Integrin Inhibitors ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Integrin Inhibitors Growth Accelerators and Market Barriers
Table 37. North America Integrin Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Integrin Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Integrin Inhibitors Growth Accelerators and Market Barriers
Table 40. Europe Integrin Inhibitors Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Integrin Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Integrin Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Integrin Inhibitors Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Integrin Inhibitors Growth Accelerators and Market Barriers
Table 45. Southeast Asia Integrin Inhibitors Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Integrin Inhibitors Investment Opportunities and Key Challenges
Table 47. Central and South America Integrin Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Integrin Inhibitors Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Integrin Inhibitors Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Merck Corporation Information
Table 51. Merck Description and Major Businesses
Table 52. Merck Product Models, Descriptions and Specifications
Table 53. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Merck Sales Value Proportion by Product in 2024
Table 55. Merck Sales Value Proportion by Application in 2024
Table 56. Merck Sales Value Proportion by Geographic Area in 2024
Table 57. Merck Integrin Inhibitors SWOT Analysis
Table 58. Merck Recent Developments
Table 59. Gland Pharma

Taj Pharmaceuticals Corporation Information
Table 60. Gland Pharma

Taj Pharmaceuticals Description and Major Businesses
Table 61. Gland Pharma

Taj Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Gland Pharma

Taj Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Gland Pharma

Taj Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Gland Pharma

Taj Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Gland Pharma

Taj Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Gland Pharma

Taj Pharmaceuticals Integrin Inhibitors SWOT Analysis
Table 67. Gland Pharma

Taj Pharmaceuticals Recent Developments
Table 68. GlaxoSmithKline Corporation Information
Table 69. GlaxoSmithKline Description and Major Businesses
Table 70. GlaxoSmithKline Product Models, Descriptions and Specifications
Table 71. GlaxoSmithKline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. GlaxoSmithKline Sales Value Proportion by Product in 2024
Table 73. GlaxoSmithKline Sales Value Proportion by Application in 2024
Table 74. GlaxoSmithKline Sales Value Proportion by Geographic Area in 2024
Table 75. GlaxoSmithKline Integrin Inhibitors SWOT Analysis
Table 76. GlaxoSmithKline Recent Developments
Table 77. Takeda Corporation Information
Table 78. Takeda Description and Major Businesses
Table 79. Takeda Product Models, Descriptions and Specifications
Table 80. Takeda Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Takeda Sales Value Proportion by Product in 2024
Table 82. Takeda Sales Value Proportion by Application in 2024
Table 83. Takeda Sales Value Proportion by Geographic Area in 2024
Table 84. Takeda Integrin Inhibitors SWOT Analysis
Table 85. Takeda Recent Developments
Table 86. Correvio Corporation Information
Table 87. Correvio Description and Major Businesses
Table 88. Correvio Product Models, Descriptions and Specifications
Table 89. Correvio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Correvio Sales Value Proportion by Product in 2024
Table 91. Correvio Sales Value Proportion by Application in 2024
Table 92. Correvio Sales Value Proportion by Geographic Area in 2024
Table 93. Correvio Integrin Inhibitors SWOT Analysis
Table 94. Correvio Recent Developments
Table 95. Medicure Corporation Information
Table 96. Medicure Description and Major Businesses
Table 97. Medicure Product Models, Descriptions and Specifications
Table 98. Medicure Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Medicure Recent Developments
Table 100. Johnson & Johnson Corporation Information
Table 101. Johnson & Johnson Description and Major Businesses
Table 102. Johnson & Johnson Product Models, Descriptions and Specifications
Table 103. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Johnson & Johnson Recent Developments
Table 105. Eli Lilly Corporation Information
Table 106. Eli Lilly Description and Major Businesses
Table 107. Eli Lilly Product Models, Descriptions and Specifications
Table 108. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Eli Lilly Recent Developments
Table 110. Bio-Thera Solutions Corporation Information
Table 111. Bio-Thera Solutions Description and Major Businesses
Table 112. Bio-Thera Solutions Product Models, Descriptions and Specifications
Table 113. Bio-Thera Solutions Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Bio-Thera Solutions Recent Developments
Table 115. Biogen Corporation Information
Table 116. Biogen Description and Major Businesses
Table 117. Biogen Product Models, Descriptions and Specifications
Table 118. Biogen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Biogen Recent Developments
Table 120. Novartis Corporation Information
Table 121. Novartis Description and Major Businesses
Table 122. Novartis Product Models, Descriptions and Specifications
Table 123. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Novartis Recent Developments
Table 125. Sandoz Corporation Information
Table 126. Sandoz Description and Major Businesses
Table 127. Sandoz Product Models, Descriptions and Specifications
Table 128. Sandoz Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Sandoz Recent Developments
Table 130. Polpharma Biologics Corporation Information
Table 131. Polpharma Biologics Description and Major Businesses
Table 132. Polpharma Biologics Product Models, Descriptions and Specifications
Table 133. Polpharma Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Polpharma Biologics Recent Developments
Table 135. Alvotech Corporation Information
Table 136. Alvotech Description and Major Businesses
Table 137. Alvotech Product Models, Descriptions and Specifications
Table 138. Alvotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Alvotech Recent Developments
Table 140. Yangtze River Pharmaceutical Corporation Information
Table 141. Yangtze River Pharmaceutical Description and Major Businesses
Table 142. Yangtze River Pharmaceutical Product Models, Descriptions and Specifications
Table 143. Yangtze River Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 144. Yangtze River Pharmaceutical Recent Developments
Table 145. Lunan Pharma Corporation Information
Table 146. Lunan Pharma Description and Major Businesses
Table 147. Lunan Pharma Product Models, Descriptions and Specifications
Table 148. Lunan Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 149. Lunan Pharma Recent Developments
Table 150. Kelun Pharma Corporation Information
Table 151. Kelun Pharma Description and Major Businesses
Table 152. Kelun Pharma Product Models, Descriptions and Specifications
Table 153. Kelun Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 154. Kelun Pharma Recent Developments
Table 155. Grand Pharmaceutical Corporation Information
Table 156. Grand Pharmaceutical Description and Major Businesses
Table 157. Grand Pharmaceutical Product Models, Descriptions and Specifications
Table 158. Grand Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 159. Grand Pharmaceutical Recent Developments
Table 160. Tianjin Chase Sun Pharma Corporation Information
Table 161. Tianjin Chase Sun Pharma Description and Major Businesses
Table 162. Tianjin Chase Sun Pharma Product Models, Descriptions and Specifications
Table 163. Tianjin Chase Sun Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 164. Tianjin Chase Sun Pharma Recent Developments
Table 165. SJZ No.4 Pharmaceutical Corporation Information
Table 166. SJZ No.4 Pharmaceutical Description and Major Businesses
Table 167. SJZ No.4 Pharmaceutical Product Models, Descriptions and Specifications
Table 168. SJZ No.4 Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 169. SJZ No.4 Pharmaceutical Recent Developments
Table 170. Huadong Medicin Corporation Information
Table 171. Huadong Medicin Description and Major Businesses
Table 172. Huadong Medicin Product Models, Descriptions and Specifications
Table 173. Huadong Medicin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 174. Huadong Medicin Recent Developments
Table 175. Key Raw Materials Distribution
Table 176. Raw Materials Key Suppliers
Table 177. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 178. Milestones in Production Technology Evolution
Table 179. Distributors List
Table 180. Market Trends and Market Evolution
Table 181. Market Drivers and Opportunities
Table 182. Market Challenges, Risks, and Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources


List of Figures
Figure 1. Integrin Inhibitors Product Picture
Figure 2. Global Integrin Inhibitors Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Antibodies Product Picture
Figure 4. Small Molecules Product Picture
Figure 5. Others Product Picture
Figure 6. Global Integrin Inhibitors Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Cardiovascular Disease
Figure 8. Autoimmune Disease
Figure 9. Tumor
Figure 10. Other
Figure 11. Integrin Inhibitors Report Years Considered
Figure 12. Global Integrin Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 14. Global Integrin Inhibitors Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Integrin Inhibitors Revenue Market Share by Region (2020-2031)
Figure 16. Global Integrin Inhibitors Sales (2020-2031) & (K Units)
Figure 17. Global Integrin Inhibitors Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Integrin Inhibitors Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Integrin Inhibitors Sales Volume Market Share in 2024
Figure 20. Global Integrin Inhibitors Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Antibodies Revenue Market Share by Manufacturer in 2024
Figure 23. Small Molecules Revenue Market Share by Manufacturer in 2024
Figure 24. Others Revenue Market Share by Manufacturer in 2024
Figure 25. Global Integrin Inhibitors Sales Market Share by Type (2020-2031)
Figure 26. Global Integrin Inhibitors Revenue Market Share by Type (2020-2031)
Figure 27. Global Integrin Inhibitors Sales Market Share by Application (2020-2031)
Figure 28. Global Integrin Inhibitors Revenue Market Share by Application (2020-2031)
Figure 29. North America Integrin Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 30. North America Integrin Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Integrin Inhibitors Sales Revenue (US$ Million) in 2024
Figure 32. North America Integrin Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 33. North America Integrin Inhibitors Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Integrin Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 35. North America Integrin Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Integrin Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 40. Europe Integrin Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Integrin Inhibitors Sales Revenue (US$ Million) in 2024
Figure 42. Europe Integrin Inhibitors Sales Volume (K Units) by Type (2020-2031)
Figure 43. Europe Integrin Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Integrin Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 45. Europe Integrin Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 47. France Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Integrin Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 52. Asia-Pacific Integrin Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Integrin Inhibitors Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Integrin Inhibitors Sales Volume (K Units) by Type (2020- 2031)
Figure 55. Asia-Pacific Integrin Inhibitors Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Integrin Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 57. Asia-Pacific Integrin Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 62. India Integrin Inhibitors Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Integrin Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 64. Central and South America Integrin Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Integrin Inhibitors Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Integrin Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 67. Central and South America Integrin Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Integrin Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 69. Central and South America Integrin Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Integrin Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Integrin Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Integrin Inhibitors Sales YoY (2020-2031) & (K Units)
Figure 73. Middle East and Africa Integrin Inhibitors Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Integrin Inhibitors Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Integrin Inhibitors Sales Volume (K Units) by Type (2021-2031)
Figure 76. South America Integrin Inhibitors Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Integrin Inhibitors Sales Volume (K Units) by Application (2020-2031)
Figure 78. Middle East and Africa Integrin Inhibitors Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Integrin Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Integrin Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Integrin Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Integrin Inhibitors Revenue (2020-2025) & (US$ Million)
Figure 83. Integrin Inhibitors Industry Chain Mapping
Figure 84. Regional Integrin Inhibitors Manufacturing Base Distribution (%)
Figure 85. Global Integrin Inhibitors Production Market Share by Region (2020-2031)
Figure 86. Integrin Inhibitors Production Process
Figure 87. Regional Integrin Inhibitors Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit